Pfizer Price to Sales Ratio 2010-2024 | PFE

Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of November 04, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pfizer P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-01 28.09 2.69
2024-09-30 28.94 $10.46 2.77
2024-06-30 27.60 $9.70 2.85
2024-03-31 26.97 $9.64 2.80
2023-12-31 27.56 $10.26 2.69
2023-09-30 31.32 $12.08 2.59
2023-06-30 34.25 $13.70 2.50
2023-03-31 37.69 $16.28 2.31
2022-12-31 46.90 $17.51 2.68
2022-09-30 39.71 $17.45 2.28
2022-06-30 47.20 $17.69 2.67
2022-03-31 46.24 $16.16 2.86
2021-12-31 52.35 $14.27 3.67
2021-09-30 37.80 $12.12 3.12
2021-06-30 34.10 $9.75 3.50
2021-03-31 31.24 $8.17 3.82
2020-12-31 31.40 $7.41 4.24
2020-09-30 29.38 $5.70 5.15
2020-06-30 25.92 $6.12 4.23
2020-03-31 25.61 $6.70 3.82
2019-12-31 30.43 $7.19 4.23
2019-09-30 27.64 $7.06 3.92
2019-06-30 33.01 $7.03 4.69
2019-03-31 32.08 $6.96 4.61
2018-12-31 32.69 $6.81 4.80
2018-09-30 32.75 $8.88 3.69
2018-06-30 26.73 $8.83 3.03
2018-03-31 25.90 $8.71 2.97
2017-12-31 26.19 $8.79 2.98
2017-09-30 25.58 $8.65 2.96
2017-06-30 23.84 $8.61 2.77
2016-12-31 22.60 $8.56 2.64
2016-09-30 23.34 $8.59 2.72
2016-06-30 24.05 $8.41 2.86
2016-03-31 20.07 $8.17 2.46
2015-12-31 21.64 $7.81 2.77
2015-09-30 20.88 $7.60 2.75
2015-06-30 22.12 $7.60 2.91
2015-03-31 22.76 $7.68 2.96
2014-12-31 20.20 $7.71 2.62
2014-09-30 19.01 $7.63 2.49
2014-06-30 18.92 $7.60 2.49
2014-03-31 20.29 $7.44 2.73
2013-12-31 19.18 $7.40 2.59
2013-09-30 17.85 $7.14 2.50
2013-06-30 17.27 $6.97 2.48
2013-03-31 17.64 $7.00 2.52
2012-12-31 15.20 $7.25 2.10
2012-09-30 14.92 $6.99 2.13
2012-06-30 13.69 $7.39 1.85
2012-03-31 13.35 $7.62 1.75
2011-12-31 12.62 $7.71 1.64
2011-09-30 10.21 $8.17 1.25
2011-06-30 11.77 $8.03 1.47
2011-03-31 11.49 $8.08 1.42
2010-12-31 9.80 $8.07 1.21
2010-09-30 9.51 $8.40 1.13
2010-06-30 7.82 $8.13 0.96
2010-03-31 9.30 $7.63 1.22
2009-12-31 9.77 $7.20 1.36
2009-09-30 8.81 $7.05 1.25
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $159.177B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69